Open in Screener

NTLA

Intellia Therapeutics Inc

Sep 16 • 02:29PM ET

12.31

+0.74 6.35 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK VTI ARKG IWM VB XBI VBK VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-4.69	Insider Own	5.81%	Shs Outstand	105.33M	Perf Week	3.58%
Market Cap	1.32B	Forward P/E	-	EPS next Y	-3.85	Insider Trans	1.39%	Shs Float	101.11M	Perf Month	11.97%
Enterprise Value	963.66M	PEG	-	EPS next Q	-1.01	Inst Own	87.91%	Short Float	27.43%	Perf Quarter	37.33%
Income	-480.19M	P/S	24.99	EPS this Y	21.07%	Inst Trans	-1.61%	Short Ratio	5.97	Perf Half Y	28.44%
Sales	52.86M	P/B	1.81	EPS next Y	6.97%	ROA	-45.94%	Short Interest	27.74M	Perf YTD	5.53%
Book/sh	6.79	P/C	2.87	EPS next 5Y	31.79%	ROE	-56.95%	52W High	23.76 -48.21%	Perf Year	-40.47%
Cash/sh	4.28	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-60.72%	52W Low	5.90 108.56%	Perf 3Y	-80.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	80.76%	Volatility	6.44% 5.45%	Perf 5Y	-34.62%
Dividend TTM	-	EV/Sales	18.23	EPS Y/Y TTM	14.42%	Oper. Margin	-956.39%	ATR (14)	0.70	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.19	Sales Y/Y TTM	14.99%	Profit Margin	-908.48%	RSI (14)	61.44	Recom	1.59
Dividend Gr. 3/5Y	- -	Current Ratio	5.19	EPS Q/Q	35.60%	SMA20	8.52%	Beta	2.29	Target Price	32.78
Payout	-	Debt/Eq	0.14	Sales Q/Q	104.76%	SMA50	5.47%	Rel Volume	1.23	Prev Close	11.57
Employees	403	LT Debt/Eq	0.11	Earnings	Aug 07 BMO	SMA200	19.30%	Avg Volume	4.64M	Price	12.31
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.70% 19.85%	Trades		Volume	4,455,552	Change	6.35%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144

Show Previous Ratings

Sep-11-25 03:45AM	Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% (Motley Fool)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Sep-02-25 03:46PM	Cathie Wood Pours $4 Million Into This High-Growth Biotech Stock (GuruFocus.com)
09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
11:15AM	Loading…
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
10:59AM	Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here? (Barchart)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-11-25 07:43AM	Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus (Zacks)
Aug-08-25 11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks) -5.85%
06:05AM	Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 \| Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9 (GlobeNewswire)
03:55AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Aug-07-25 08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Aug-01-25 07:30AM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:12PM	Loading…
Jul-31-25 01:12PM	BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock (Zacks) -5.60%
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Jul-30-25 09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-28-25 08:41AM	Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus (Zacks)
Jul-15-25 04:27PM	Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (MarketBeat)
Jul-14-25 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-08-25 12:54PM	The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. (Barchart) +8.49%
Jul-07-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:46AM	Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
Jul-03-25 09:18AM	Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-25-25 10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
Jun-23-25 01:41AM	Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress (Insider Monkey)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily) +6.92%
01:32PM	Loading…
01:32PM	Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential (Insider Monkey)
05:44AM	FDA clears CSLs swelling disease drug; Regeneron loses 23andMe auction (BioPharma Dive)
Jun-15-25 10:45AM	Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.73%
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
09:55AM	How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -7.79%
05:56AM	Intellia stock dips following safety event in Phase III gene therapy trial (Clinical Trials Arena)
May-29-25 08:30PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.88%
08:18AM	Intellia stock tumbles on safety concerns (Investing.com)
07:16AM	Intellia filing spurs safety concerns over CRISPR drug (BioPharma Dive)
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks) +6.59%
May-18-25 07:25AM	Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting (GlobeNewswire)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +5.26%
May-15-25 09:55AM	Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? (Zacks)
May-09-25 12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:12AM	Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-08-25 05:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.58%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks)
11:57AM	Intellia Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.10%
08:40AM	CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-01-25 10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Apr-30-25 10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +8.17%
Apr-29-25 09:55AM	Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet (Zacks)
Apr-23-25 09:50AM	Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation (PR Newswire)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +9.54%
Apr-11-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +9.45%
Apr-09-25 09:42AM	Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.74%
Apr-04-25 01:42PM	Intellia Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information NTLA (GlobeNewswire)
07:28AM	Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN (Clinical Trials Arena)
Apr-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.62%
12:40PM	IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility (Pharmaceutical Technology)
07:30AM	Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Apr-01-25 12:41PM	Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? (Insider Monkey) -6.40%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 10:10AM	Intellia Focuses on Pipeline Development Amid Stiff Competition (Zacks) -11.90%
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
06:24AM	Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (Seeking Alpha)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
Mar-26-25 07:30AM	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-21-25 11:25AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-05-25 09:34AM	Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls (The Fly)
Mar-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-25 06:01AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -7.09%
02:10AM	Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
01:17AM	Q4 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-26-25 08:56PM	Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) -6.95%

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHASE WILLIAM J	Director	Aug 20 '25	Buy	10.03	100,000	1,003,000	134,693	Aug 22 04:30 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 23 '25	Sale	14.02	7,462	104,617	106,062	Jul 25 04:05 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM
Bhanji Muna	Director	Jan 29 '25	Sale	9.97	265	2,642	19,468	Jan 31 04:17 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 03 '25	Sale	12.18	1,372	16,711	45,640	Jan 07 05:23 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '25	Sale	12.18	7,074	86,161	74,497	Jan 07 05:22 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '25	Sale	12.18	9,557	116,404	87,666	Jan 07 05:20 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '25	Sale	12.18	6,502	79,194	59,878	Jan 07 05:20 PM
LEONARD JOHN M	President and CEO	Jan 03 '25	Sale	12.18	26,807	326,509	941,115	Jan 07 05:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '25	Sale	12.18	8,966	109,206	77,388	Jan 07 05:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '25	Sale	12.18	7,422	90,400	64,048	Jan 06 04:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 02 '25	Sale	12.03	556	6,689	71,470	Jan 06 04:16 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 02 '24	Sale	19.01	2,012	38,248	47,012	Oct 04 05:29 PM

Open in Screener

IQV

IQVIA Holdings Inc

Sep 16 • 02:29PM ET

186.51

+0.54 0.29 %

Healthcare • Diagnostics & Research • USA • NYSE

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO SPY IVV VTV XLV IBB COWZ RSP

Index	S&P 500	P/E	27.02	EPS (ttm)	6.90	Insider Own	0.86%	Shs Outstand	170.00M	Perf Week	-1.65%
Market Cap	31.71B	Forward P/E	14.49	EPS next Y	12.87	Insider Trans	-0.43%	Shs Float	168.53M	Perf Month	-2.40%
Enterprise Value	45.23B	PEG	3.20	EPS next Q	2.97	Inst Own	101.10%	Short Float	2.93%	Perf Quarter	17.12%
Income	1.24B	P/S	2.02	EPS this Y	6.61%	Inst Trans	5.14%	Short Ratio	2.74	Perf Half Y	0.87%
Sales	15.70B	P/B	5.49	EPS next Y	8.49%	ROA	4.50%	Short Interest	4.94M	Perf YTD	-5.09%
Book/sh	33.99	P/C	14.49	EPS next 5Y	8.43%	ROE	19.80%	52W High	248.03 -24.80%	Perf Year	-21.77%
Cash/sh	12.87	P/FCF	15.77	EPS past 3/5Y	14.76% 50.90%	ROIC	6.13%	52W Low	134.65 38.52%	Perf 3Y	-16.43%
Dividend Est.	-	EV/EBITDA	13.37	Sales past 3/5Y	3.54% 6.79%	Gross Margin	27.09%	Volatility	2.74% 2.46%	Perf 5Y	15.80%
Dividend TTM	-	EV/Sales	2.88	EPS Y/Y TTM	-10.72%	Oper. Margin	14.40%	ATR (14)	5.02	Perf 10Y	150.85%
Dividend Ex-Date	-	Quick Ratio	0.84	Sales Y/Y TTM	3.53%	Profit Margin	7.88%	RSI (14)	50.77	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	0.84	EPS Q/Q	-22.02%	SMA20	-0.71%	Beta	1.33	Target Price	214.16
Payout	0.00%	Debt/Eq	2.72	Sales Q/Q	5.27%	SMA50	2.06%	Rel Volume	0.29	Prev Close	185.97
Employees	88000	LT Debt/Eq	2.49	Earnings	Jul 22 BMO	SMA200	4.92%	Avg Volume	1.80M	Price	186.51
IPO	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.42% 1.19%	Trades		Volume	406,675	Change	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$225
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265
Dec-06-22	Initiated	Cowen	Outperform	$251
Nov-17-22	Downgrade	Citigroup	Buy → Neutral	$275 → $245
Aug-25-22	Initiated	Credit Suisse	Outperform	$300
Jul-15-22	Initiated	SVB Leerink	Outperform	$256
May-24-22	Initiated	Guggenheim	Buy	$244

Show Previous Ratings

Today 08:00AM	IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships (Business Wire)
Sep-11-25 02:16PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
06:09AM	How Is IQVIA Holdings' Stock Performance Compared to Other Health Tech Stocks? (Barchart)
Sep-10-25 08:00AM	IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management (Business Wire)
04:54AM	IQVIA Holdings Inc. (IQV) and Flagship Pioneering Partner to Accelerate Growth of Breakthrough Life Sciences Companies (Insider Monkey)
12:11PM	Loading…
Sep-09-25 12:11PM	Jefferies backs IQVIA and Charles River, cuts ICON on customer losses (Investing.com)
Sep-03-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Sep-02-25 09:00AM	IQVIA Announces CFO Transition in Early 2026 (Business Wire)
Aug-29-25 11:30AM	Why Is DexCom (DXCM) Down 7% Since Last Earnings Report? (Zacks)
Aug-28-25 08:00AM	IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies (PR Newswire)
Aug-27-25 09:55AM	IQVIA Holdings Inc. (IQV): A Bull Case Theory (Insider Monkey)
Aug-22-25 08:29AM	What Are Wall Street Analysts' Target Price for IQVIA Holdings Stock? (Barchart)
Aug-21-25 11:30AM	IQVIA (IQV) Down 1.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-18-25 11:31PM	Q2 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
09:00AM	IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes (Business Wire)
09:40AM	Loading…
Aug-14-25 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
02:42AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Aug-13-25 10:57AM	UMAC Gears Up to Report Q2 Earnings: What's in the Offing? (Zacks)
Aug-11-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
05:19AM	Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion (PR Newswire)
Aug-06-25 06:42PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:24PM	Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss (Zacks)
Aug-05-25 12:23PM	Gartner Earnings Surpass Estimates in Q2, Revenues Increase Y/Y (Zacks)
Jul-30-25 10:42AM	Verisk Earnings & Revenues Surpass Estimates in Q2, Increase Y/Y (Zacks)
Jul-29-25 12:44PM	WM Earnings & Revenues Beat Estimates in Q2, Increase Y/Y (Zacks)
12:41PM	Fiserv Q2 Earnings Beat Estimates on Strong Margins, Revenues Miss (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
01:34AM	5 Revealing Analyst Questions From IQVIA's Q2 Earnings Call (StockStory)
Jul-28-25 10:45AM	IQVIA (IQV) Reliance on International Sales: What Investors Need to Know (Zacks)
Jul-24-25 06:37PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
11:17AM	Loading…
11:17AM	Veeva's Vault Vision: Can It Thrive After Parting With Salesforce? (Zacks)
Jul-23-25 02:23PM	IQVIA Holdings (IQV) Snaps 2-Day Losses on Higher-than-Expected Earnings (Insider Monkey)
01:31PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
09:58AM	Fiserv's Q2 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
08:37AM	Stock Market News for Jul 23, 2025 (Zacks)
03:08AM	IQVIA Holdings Inc (IQV) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic AI ... (GuruFocus.com)
01:32AM	IQV Q2 Deep Dive: AI Initiatives and Pipeline Growth Drive Outperformance Amid Margin Pressures (StockStory)
Jul-22-25 05:55PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research) +17.88%
04:38PM	S&P 500 Gains & Losses Today: Homebuilder Stocks Soar; Lockheed Martin Loses Altitude (Investopedia)
04:06PM	Medpace Surges 55% On 'Shockingly Strong' Report; Pulling Iqvia Higher (Investor's Business Daily)
02:53PM	IQVIA Leads S&P 500 Gainers on Better-Than-Expected Earnings (Investopedia)
12:23PM	Top Stock Movers Now: GM, Lockheed Martin, IQVIA, DR Horton, and More (Investopedia)
12:15PM	IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y (Zacks)
11:55AM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
09:08AM	Iqvia Surges As 'Pluses' Outweigh 'Minuses' In Its Second-Quarter Report (Investor's Business Daily)
08:15AM	IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:37AM	IQVIA (NYSE:IQV) Beats Q2 Sales Targets, Stock Soars (StockStory)
07:16AM	IQVIA: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Second-Quarter 2025 Results (Business Wire)
Jul-20-25 11:02PM	IQVIA Earnings: What To Look For From IQV (StockStory)
Jul-17-25 09:15AM	Countdown to IQVIA (IQV) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:52AM	What Makes IQVIA Holdings (IQV) an Investment Bet? (Insider Monkey)
08:08AM	Is IQVIA Holdings (IQV) an Attractive Investment Opportunity? (Insider Monkey)
Jul-16-25 10:00AM	Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:42AM	IQVIA Gears Up to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-15-25 05:06PM	Top Stock Reports for Amazon.com, Meta Platforms & Shopify (Zacks)
10:00AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
12:05AM	3 Reasons IQV is Risky and 1 Stock to Buy Instead (StockStory)
Jul-11-25 09:45AM	Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term (Zacks)
Jul-10-25 11:40AM	IQVIA Unveils New Custom AI Agents with NVIDIA (Insider Monkey)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-09-25 11:52AM	Veeva Expands Market Reach Through Targeted Strategic Partnerships (Zacks)
Jul-08-25 12:05PM	VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? (Zacks)
09:34AM	Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning (PR Newswire)
05:08AM	What to Expect From IQVIA Holdings' Q2 2025 Earnings Report (Barchart)
Jul-02-25 10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jul-01-25 07:00AM	IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025 (Business Wire)
Jun-30-25 12:39AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-26-25 06:01PM	The Top 5 Analyst Questions From IQVIA's Q1 Earnings Call (StockStory)
10:15AM	Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. (Investor's Business Daily)
Jun-17-25 10:18AM	AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers (PR Newswire)
Jun-16-25 11:34PM	Drug Development Inputs & Services Stocks Q1 Highlights: IQVIA (NYSE:IQV) (StockStory)
09:00AM	IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement' (Business Wire)
Jun-11-25 07:00AM	IQVIA Launches New AI Agents for Life Sciences and Healthcare (Business Wire)
Jun-05-25 11:44AM	Doximity Declines 4.4% in a Month: How to Play the Stock Now? (Zacks)
Jun-02-25 04:37PM	IQVIA Announces Pricing of Senior Notes (Business Wire)
08:10AM	IQVIA Announces Offering of Senior Notes (Business Wire)
May-31-25 03:00AM	Ipca Laboratories Ltd (BOM:524494) Q4 2025 Earnings Call Highlights: Strong Domestic Growth and ... (GuruFocus.com)
May-27-25 07:00AM	Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF (PR Newswire)
May-19-25 08:48AM	IQV Q1 Earnings Call: Real-World Evidence Drives Outperformance Amid Sector Uncertainty (StockStory)
05:40AM	IQVIA and SCRI partner to enhance oncology trials (Clinical Trials Arena)
May-16-25 08:00AM	IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials (Business Wire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -5.88%
May-13-25 09:16AM	Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends (Zacks)
May-07-25 06:03PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
04:15PM	IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13 (Business Wire)
03:12AM	IQVIA Holdings Inc (IQV) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
02:44AM	Q1 2025 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 09:00PM	IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
12:33PM	IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y (Zacks)
08:10AM	IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:10AM	IQVIA: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports First-Quarter 2025 Results (Business Wire)
May-05-25 03:05AM	After an up and down year, pharmas R&D landscape is shifting again (Pharma Voice)
May-01-25 09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:15AM	IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Apr-30-25 10:01AM	RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-29-25 10:01AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-28-25 06:50PM	IQVIA Holdings Inc. (IQV): Among Billionaire Israel Englander's Stock Picks with Huge Upside Potential (Insider Monkey)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cherofsky Keriann	See Remarks	Jul 23 '25	Sale	191.53	549	105,150	2,910	Jul 25 05:01 PM
Sherbet Eric	See Remarks	Jul 23 '25	Option Exercise	97.20	11,870	1,153,764	32,978	Jul 25 05:00 PM
Sherbet Eric	See Remarks	Jul 23 '25	Sale	190.05	5,800	1,102,290	27,178	Jul 25 05:00 PM
ERIC SHERBET	Officer	Jul 23 '25	Proposed Sale	190.05	5,800	1,102,262		Jul 23 05:53 PM
KERIANN CHEROFSKY	Officer	Jul 23 '25	Proposed Sale	191.53	549	105,150		Jul 23 04:01 PM
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12 05:11 PM
DANHAKL JOHN G	Director	Dec 03 '24	Buy	200.58	1,275	255,740	1,275	Feb 07 07:03 PM

NTLA

Intellia Therapeutics Inc

IQV

IQVIA Holdings Inc

Upgrade your FINVIZ experience